Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.
NewLink Genetics, the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market.
Merck has snapped up the exclusive rights to NewLink Genetics' Ebola vaccine, which is being rushed into a Phase III study as part of a global effort to head off an outbreak in West Africa.
Merck may soon be the next Big Pharma to step into the Ebola vaccine arena.
To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.
How low should LDL go? That is the debate that continues among heart doctors since the American Heart Association upended statin prescribing guidelines last year, and Merck's Zetia is now in the middle of the muddle.
The Fred Hutchinson Cancer Research Center has tapped well-known drug investigator Gary Gilliland to become its new president.
The U.K. is striving to brand itself as a hotbed for biotech R&D, promising new funds for startups, pledging to speed up its approval process and courting some major players to deepen their roots in the country.
Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.
When Merck's Indian JV, Hilleman Laboratories, teamed up in June with Swedish biotech Gotovax AB, the plan was to get an affordable cholera vaccine to the developing world. Just a few months out, it's inked a pact to make that happen faster.